[{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Seribantumab","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Aisling Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Seribantumab","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Aisling Capital","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Aisling Capital"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Seribantumab","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Seribantumab","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Seribantumab","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"US Oncology Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Seribantumab","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Elevation Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Elevation Oncology"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Seribantumab","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":1.1799999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1799999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Elevation Oncology \/ Elevation Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Elevation Oncology"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elevation Oncology","amount2":0.37,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.37,"dosageForm":"Oral","sponsorNew":"Elevation Oncology \/ Elevation Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Elevation Oncology \/ Elevation Oncology"}]
Find Clinical Drug Pipeline Developments & Deals by Elevation Oncology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
